Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of share options, 50,285 new ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application will be made to the London Stock Exchange for the admission of the 50,285 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 3 May 2019.
Total Voting Rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 16,297,268 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 16,297,268.
The figure of 16,297,268 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.
Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.
To learn more about Instem solutions and its mission, please visit instem.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Phil Reason, chief executive of healthcare AI software group Instem PLC (LON:INS), says business was strong across all areas of the group in the first six months of 2019.
Even a change from licences to a SaaS or pay-as you-use model has gone smoothly, he says, with cash inflows strong...